Abaxis Inc (NASDAQ:ABAX) insider Kenneth Aron sold 1,412 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $69.59, for a total transaction of $98,261.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Abaxis Inc (NASDAQ:ABAX) traded up $0.57 during trading hours on Friday, reaching $71.69. 117,283 shares of the company’s stock traded hands, compared to its average volume of 152,697. The stock has a market cap of $1,614.28, a price-to-earnings ratio of 66.38, a price-to-earnings-growth ratio of 11.68 and a beta of 1.27. Abaxis Inc has a 52-week low of $43.66 and a 52-week high of $78.53.
Abaxis (NASDAQ:ABAX) last posted its quarterly earnings data on Thursday, January 25th. The medical research company reported $0.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.05. The firm had revenue of $59.70 million during the quarter, compared to analyst estimates of $59.37 million. Abaxis had a net margin of 10.51% and a return on equity of 10.09%. The company’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter last year, the business posted $0.30 EPS. equities research analysts expect that Abaxis Inc will post 1.2 earnings per share for the current year.
Several brokerages recently weighed in on ABAX. Bank of America raised their price target on shares of Abaxis from $46.00 to $48.00 and gave the company a “sell” rating in a research report on Thursday, February 8th. Zacks Investment Research cut shares of Abaxis from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. BidaskClub raised shares of Abaxis from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. Canaccord Genuity reaffirmed a “hold” rating and issued a $65.00 price target on shares of Abaxis in a research report on Monday, January 29th. Finally, Stifel Nicolaus raised their price target on shares of Abaxis from $48.00 to $57.00 and gave the company a “hold” rating in a research report on Friday, January 26th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the stock. Abaxis has an average rating of “Hold” and a consensus price target of $62.30.
A number of large investors have recently bought and sold shares of ABAX. Parametric Portfolio Associates LLC increased its stake in Abaxis by 5.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 25,386 shares of the medical research company’s stock valued at $1,346,000 after buying an additional 1,424 shares during the last quarter. State Street Corp increased its stake in Abaxis by 1.0% in the 2nd quarter. State Street Corp now owns 569,671 shares of the medical research company’s stock valued at $30,203,000 after buying an additional 5,672 shares during the last quarter. First Trust Advisors LP purchased a new stake in Abaxis in the 3rd quarter valued at about $430,000. Victory Capital Management Inc. increased its stake in Abaxis by 42.8% in the 3rd quarter. Victory Capital Management Inc. now owns 3,675 shares of the medical research company’s stock valued at $164,000 after buying an additional 1,101 shares during the last quarter. Finally, Stevens Capital Management LP purchased a new stake in Abaxis in the 3rd quarter valued at about $372,000. Hedge funds and other institutional investors own 96.64% of the company’s stock.
WARNING: This report was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3253980/abaxis-inc-abax-insider-kenneth-aron-sells-1412-shares.html.
Abaxis Company Profile
Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.
Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with MarketBeat.com's FREE daily email newsletter.